Kostaive

Product

Last mentioned: Mar 2, 2026

Timeline

Mar 3, 2026
Q4 Earnings Release

Both companies scheduled to report full-year 2025 financial results.
Sep 15, 2025
ARCT-032 Phase 1b

Arcturus releases positive interim data for Cystic Fibrosis candidate.
Nov 28, 2023
Kostaive Approval

Japan's MHLW approves the first sa-mRNA COVID-19 vaccine.

Stories mentioning Kostaive 1

Biotech Earnings Preview: Arcturus and Rigel Set for Pivotal Q4 Reports

Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, with investors focusing on Arcturus's sa-mRNA commercialization and Rigel's path to sustained profitability. Both companies represent different archetypes of the biotech sector's shift toward commercial execution.

Mar 2, 2026 2 sources